Breast Cancer | Treatment Sequencing | US | 2024
KEY BENEFITS AND USES
- Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
- Drill down into physicians’ treatment sequences and understand whom to position against or how to defend share.
- Identify untapped treatment scenarios and key competitors to aid trial design.
- Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
- Discover untapped populations to expand product share and drive strategic decisions.
QUESTIONS ANSWERED
- Where is my product positioned versus competitors in the treatment journey?
- What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
- What are the market-relevant treatment scenarios according to oncology experts?
- Where are the untapped business opportunities on which I can capitalize?
- How can I optimize trial design and ensure a competitive edge for my pipeline asset?
GEOGRAPHY
United States.
PRIMARY MARKET RESEARCH
Survey of 101 U.S. medical oncologists.
PRODUCT DESCRIPTION
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts’ assumptions.
Related Market Assessment Reports
Report
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel reimbursement approaches are rapidly gaining importance. To assist developers of gene…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicles, characterized by painful, inflamed lesions often filled with fluid or pus. AbbVie’s Humira (…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
